Trial Breakthrough: Immunotherapy + Chemo Before Surgery 🩺 | Living Room® Highlights скачать в хорошем качестве

Trial Breakthrough: Immunotherapy + Chemo Before Surgery 🩺 | Living Room® Highlights

This Lung Cancer Living Room® highlight video features Dr. Joshua K. Sabari, a leading medical oncologist from NYU Langone Health, breaking down a seismic shift discussed at ASCO 2025 in how we treat early-stage lung cancer. We aren't just talking about small improvements; we are talking about a "practice-changing" approach that is significantly increasing cure rates for patients. 🧬 What You’ll Learn in This Episode 1. The "Combination Approach" (CheckMate 816) Historically, surgery alone often left an "unacceptably high" risk of recurrence. Dr. Sabari explains the revolutionary CheckMate 816 trial, which proved that giving immunotherapy (Nivolumab) plus chemotherapy before surgery (neoadjuvant therapy) leads to deeper, longer responses and more cures. 2. Why Biomarkers are Non-Negotiable You should not start immunotherapy until your biomarker results are back. Dr. Sabari emphasizes that 100% of his patients receive testing because it is the only way to select the "best possible treatment" for the individual. PD-L1: A marker that helps predict if you will respond well to immunotherapy. Driver Mutations: If your cancer is "ticking" because of a specific mutation like EGFR or ALK, immunotherapy is generally not the right choice. 3. Redefining "Early Stage" Dr. Sabari clarifies that "early stage" (Stages 1, 2, and 3) means the cancer is localized to the lung or nearby lymph nodes. Crucially, at these stages, treatment is curative in intent—we are playing offense to get rid of the disease for good. 4. Understanding Your Treatment Timeline: Dr. Sabari breaks down the three main ways systemic therapy is integrated with surgery: Neoadjuvant Therapy: Treatment like chemotherapy and immunotherapy given before surgery to shrink tumors and improve cure rates. Adjuvant Therapy: Treatment given after surgery to kill any remaining cancer cells and prevent recurrence. Perioperative Therapy: A comprehensive approach that includes treatment both before and after the surgical procedure. 🕒 Video Chapters 0:00 – The breakthrough in early-stage lung cancer survival 0:32 – Who should get biomarker testing? 0:51 – PD-L1 testing is essential for immunotherapy 1:07 – Finding personalized drugs with genomic testing 1:24 – Antibody-Drug Conjugates (ADCs) 1:36 – Biomarker testing to qualify for clinical trials 2:06 – What "Early-Stage" lung cancer actually means (Stages 1-3) 2:48 – CheckMate 816: A revolutionary combination 3:16 – High vs. Low PD-L1: Who benefits most? 4:30 – Neoadjuvant vs. Adjuvant: Treatment before or after surgery? 4:45 – Perioperative therapy 5:00 – CRITICAL: "You should not get immunotherapy until you know your biomarkers are negative" 6:23 – Why surgery alone is no longer the standard 7:45 – More on driver mutations not reacting as well to immunotherapy 8:45 – The exceptions: KRAS, BRAF, and MET 🔗 Resources Mentioned Full Lung Cancer Living Room® Episode (ASCO 2025 Highlights):    • Lung Cancer News and Highlights From ASCO ...   🆘 You Are Not Alone The landscape of lung cancer is changing fast, and it can be overwhelming. Please reach out if you need help navigating your diagnosis or finding a specialist. 📞 Call our HelpLine: 1-800-298-2436 📧 Email us: support@go2.org 💻 Visit us: go2.org #LungCancer #Oncology #CheckMate816 #Biomarkers #CancerResearch #Immunotherapy #NSCLC #GO2